Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease

Journal of Neuroscience

Volumn 16, Issue 9, 1996, Pages 3019-3025

  Palfi, Stéphane ^a,b   Ferrante, Robert J ^c,e   Brouillet, Emmanuel ^a   Beal, M Flint ^d   Dolan, Robert ^a   Guyot, Marie Caroline ^a   Peschanski, Marc ^b   Hantraye, Philippe ^a  

^a DIF   (France)

^b INSERM   (France)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 nitropropionic acid; apomorphine testing; baboon; basal ganglia; caudate nucleus; cognitive behavior; frontal cortex; Huntington's disease; motor behavior; object retrieval detour task

Indexed keywords

3 NITROPROPIONIC ACID; APOMORPHINE; CALBINDIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; CAUDATE NUCLEUS; COGNITIVE DEFECT; CONTROLLED STUDY; HISTOCHEMISTRY; HUNTINGTON CHOREA; IMMUNOCYTOCHEMISTRY; MOTOR DYSFUNCTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PUTAMEN; TASK PERFORMANCE;

EID: 0030001887     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/jneurosci.16-09-03019.1996     Document Type: Article

References (48)

1. Albin RL, Greenamyre JT (1992) Alternative excitotoxic hypothesis. Neurology 42:733-738.
2. Battig K, Rosvold HE, Mishkin M (1960) Comparison of the effects of frontal and caudate lesions on delayed response and alternation in monkeys. J Comp Physiol Psychol 53:400-404.
3. Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31:119-130.
4. Beal MF (1994) Neurochemistry and toxin models in Huntington's disease. Curr Opin Neurol 7:542-547.
5. Beal MF, Brouillet E, Jenkins B, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:1481-1492.
6. Beal MF, Henshaw R, Jenkins BG, Rosen BR, Schulz JB (1994) Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 36:882-888.
7. Berent S, Giordani B, Lehtinen S, Markel D, Penney JB, Buchtel HA, Starosta-Rubinstein S, Hichwa R, Young AB (1988) Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function. Ann Neurol 23:541-546.
8. Brandt J, Folstein SE, Folstein MF (1988) Differential cognitive impairment in Alzheimer's disease and Huntington's disease. Ann Neurol 23:555-561.
9. Brennan WAJ, Bird ED, Aprille JR (1985) Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 44:1948-1950.
10. Brouillet E, Hantraye P, Dolan R, Leroy-Willig A, Bottlaender M, Isacson O, Mazière M, Ferrante RJ, Beal MF (1993) Chronic administration of 3-nitropropionic acid induced selective striatal degeneration and abnormal choreiform movements in monkeys. Soc Neurosci Abstr 19:409.
11. Brouillet E, Hantraye P, Ferrante RJ, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal F (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 92:7105-7109.
12. Brouillet E, Hyman BT, Jenkins BG, Henshaw DR, Schulz JB, Sodhi P, Rosen BR, Beal MF (1994) Systemic or local administration of azide produces striatal lesions by an energy impairment-induced excitotoxic mechanism. Exp Neurol 129:175-182.
13. Butters N, Sax D, Montgomery K, Tarlow S (1978) Comparison of the neuropsychological deficits associated with early and advanced Huntington's disease. Arch Neurol 35:585-589.
14. Chavoix C, Dauvillier F, Landeau B, Le Mestric C, Huguet G, Marié RM (1994) Comparison of mnesic performance between humans and baboons with the same automated delayed nonmatching-to-sample task. Folia Primatol (Basel) 62:191-192.
15. Cummings JL (1993) Frontal-subcortical circuits and human behavior. Arch Neurol 50:873-880.
16. Diamond A (1990) Developmental time course in human infants and infant monkeys, and the neural bases of inhibitory control in reaching. Ann NY Acad Sci 608:637-669.
17. Diamond A, Goldman-Rakic PS (1985) Evidence for involvement of prefrontal cortex in cognitive changes during the first year of life: comparison of performances of human infant and rhesus monkeys on a detour task with transparent barrier. Soc Neurosci Abstr 11:832.
18. Diamond R, White RF, Myers R, Mastromauro C, Koroshetz WJ, Butters N, Rothstein DM, Moss MB, Varterling J (1992) Evidence of presymptomatic cognitive decline in Huntington's disease. J Clin Exp Neuropsychol 14:961-975.
19. Diamond A, Zola-Morgan S, Squire LR (1989) Successful performance by monkeys with lesions of the hippocampal formation on AB- and object retrieval, two tasks that mark developmental changes in human infants. Behav Neurosci 103:526-537.
20. Divac J, Rosvold HE, Szwarchart MK (1967) Behavioral effects of selective ablation of the caudate nucleus. J Comp Physiol Psychol 63:184-190.
21. Ferrante RJ, Hantraye P, Brouillet E, Kowall NW, Beal MF (1993) Striatal pathology of impaired mitochondrial metabolism in primates profiles Huntington's disease. Soc Neurosci Abstr 19:408.
22. Grafton ST, Mazziotta JC, Pahl JJ, George-Hyslop PS, Haines JL, Gusella J, Hoffman JM, Baxter LR, Phelps ME (1990) A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease. Ann Neurol 28:614-621.
23. Hantraye P, Riche D, Maziere M, Isacson O (1990) An experimental primate model of Huntington's disease: anatomical and behavioural studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol 108:91-104.
24. Hantraye P, Leroy-Willig A, Denys A, Riche D, Isacson O, Syrota A (1992a) Magnetic resonance imaging to monitor pathology of caudate-putamen after excitotoxin-induced neuronal loss in the non-human primate brain. Exp Neurol 118:18-23.
25. Hantraye P, Riche D, Maziere M, Isacson O (1992b) Intrastriatal grafting of fetal striatal cross-species cells ameliorates abnormal movements in a primate model of Huntington's disease. Proc Natl Acad Sci USA 89:4187-4190.
26. Harper PS (1991) Huntington's disease (Harper PS, ed), pp 1-429. London: WB Saunders.
27. Isacson O, Hantraye P, Riche D Schumacher JM, Maziere M (1991) The relationship between symptoms and functional anatomy in the chronic neurodegenerative diseases: from pharmacological to biological replacement therapy in Huntington's disease. In: Intracerebral transplantation in movement disorders (Lindwall O, Bjorklund A, Widner H, eds), pp 245-258. Amsterdam: Elsevier Science.
28. Jenkins BG, Koroshetz WJ, Beal MF, Rosen BR (1993) Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized proton NMR spectroscopy. Neurology 43:2689-2695.
29. Kremer B, Weber B, Hayden MR (1992) New insights into the clinical features, pathogenesis and molecular genetics of Huntington's disease. Brain Pathol 2:321-335.
30. Kuhl DE, Phelps ME, Markham CH, Metter EJ, Riege WH, Winter J (1982) Cerebral metabolism and atrophy in Huntington's disease determined bv 18FDG and computed tomographic scan. Ann Neurol 12:425-434'
31. Kuwert T, Lange HW, Langen KJ, Herzog H, Aulich A, Feinendegen LE (1990) Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. Brain 113:1405-1423.
32. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M (1991) 3-nitropropionic acid: exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18:492-498.
33. Mann VM, Cooper JM, Javoy-Agid F, Agid Y, Jenner P, Schapira AHV (1990) Mitochondrial function and parental sex effect in Huntington's disease. Lancet 336:749.
34. Martin JB, Gusella J (1986) Huntington's disease: pathologenesis and management. N Engl J Med 315:1267-1276.
35. Martin WRW, Clark C, Ammann W, Stoessl AJ, Shtyel W, Hayden MR (1992) Cortical glucose metabolism in Huntington's disease. Neurology 42:223-229.
36. Massman PJ, Delis DC, Butters N, Levin BE, Salmon DP (1990) Are all subcortical dementias alike? Verbal learning and memory in Parkinson's and Huntington's disease patients. J Clin Exp Neuropsychol 12:729-744.
37. Mazziotta JC, Phelps ME, Pahl JJ, Huang SC, Baxter LR, Riege WH, Hoffmann JM, Kuhl DE, Lanto AB, Wapenski JA, Markham CH (1987) Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. N Engl J Med 316:357-362.
38. Mendez MF, Astorna NE, Skoog-Lewandowski K (1989) Neurobehavioral changes associated with caudate lesions. Neurology 39:49-355.
39. Parker Jr WD, Boyson SJ, Luder AS, Parks JK (1990) Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 40:1231-1234.
40. Pillon B, Dubois B, Ploska A, Agid Y (1991) Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy. Neurology 41:634-643.
41. Randolph C (1991) Implicit, explicit, and semantic memory functions in Alzheimer's disease and Huntington's disease. J Clin Exp Neuropsychol 13:479-494.
42. Richfield EK, Twyman R, Berent S (1987) Neurological syndrome following bilateral damage to the head of the caudate nuclei. Ann Neurol 22:768-771.
43. Roberts AC, De Salvia MA, Wilkinson LS, Collin P, Muir JL, Everitt BJ, Robbins TW (1994) 6-hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: possible interactions with subcortical dopamine. J Neurosci 14:2531-2544.
44. Schneider JS (1992) Behavioral and neuropathological consequences of chronic exposure to low doses of the dopaminergic neurotoxin MPTP. In: The vulnerable brain and environmental risks (Isaacson RL, Jensen KF, eds), pp 293-308: New York: Plenum.
45. Taylor JR, Elsworth JD, Roth RH, Collier TJ, Sladek JR, Redmond DE (1990a) Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys. Prog Brain Res 62:543-559.
46. Taylor JR, Redmond JD, Roth RH, Sladek JR, Redmond JR (1990b) Cognitive and motor deficits in the acquisition of an object retrieval/ detour task in MPTP-treated monkeys. Brain 113:617-637.
47. The Huntington's Disease Collaborative Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983.
48. Young AB, Penney JB, Starosta-Rubenstein S, Markel DS, Berent S, Giordani B, Ehrenkaufer R, Jewett D, Hichwa R (1986) PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurologic features and functional decline. Ann Neurol 20:296-303.